(Translated from Chinese)

Receipt is hereby acknowledged of communication No. AL CHN 6/2021 of 7 June 2021 from the Working Group on discrimination against women and girls, the Working Group on the issue of human rights and transnational corporations and other business enterprises and the Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health, of the United Nations Human Rights Council. The Chinese Government wishes to respond with the following:

Xianju Pharmaceutical is a legal pharmaceutical manufacturing company. The active ingredient ethinylestradiol is produced and exported by this company, in strict compliance with the Chinese standards for Good Manufacturing Practices for medical products (or GMP), and was authorized for sale after being verified to be in compliance with the European Pharmacopoeia (EP) standards and the quality standards agreed upon by the purchasers and sellers. The recall of defective contraceptives by the Chilean Institute of Public Health is unrelated to the active ingredient, ethinylestradiol, produced by Xianju.

中华人民共和国常驻联合国日内瓦办事处和瑞士其他国际组织代表团

PERMANENT MISSION OF THE PEOPLE'S REPUBLIC OF CHINA

11 Chemin de Surville, 1213 Petit-Lancy
Tel: +41 (0)22 879 56 78 Fax: +41 (0) 22 793 70 14
Email: chinamission_gva@mfa.gov.cn Website: www.china-un.ch

No.GJ/40/2021

The Permanent Mission of the People's Republic of China to the United Nations Office at Geneva and other International Organizations in Switzerland presents its compliments to the Office of the High Commissioner for Human rights and with reference to the joint communication [AL CHN 6/ 2021] dated by 7 June 2021, has the honour to transmit herewith the reply by the Chinese Government.

The Permanent Mission of the People's Republic of China to the United Nations Office at Geneva and Other International Organizations in Switzerland avails itself of this opportunity to renew to the Office of the High Commissioner for Human Rights the assurances of its highest consideration.

Geneva, 6 August 2021

Office of the High Commissioner for Human Rights
GENEVA

联合国人权理事会消除对妇女和女童歧视问题工作组、人权与跨国公司问题工作组、健康权问题特别报告员2021年6月7日来函【AL CHN 6/2021】收悉。中国政府对来函答复如下：

仙琚制药为合法药品生产企业，该企业出口的原料药炔雌醇严格按照中国《药品生产质量管理规范》（GMP）组织生产，按欧洲药典（EP）标准以及购销双方合同约定的质量标准，检测合格后放行销售。智利公共卫生研究院召回缺陷避孕药事件与仙琚制药的原料药炔雌醇无关。